Bli medlem
Bli medlem

Du är här


BioGaia: Annual General Meeting of BioGaia

The Annual General Meeting of BioGaia AB (publ) on 10 May 2016 voted
to approve the following resolutions:

· adoption of the annual report
· discharge from liability for the Board members and the Managing

· a dividend of SEK 5.00 per share
· re-election of Board members Jan Annwall, Ewa Björling, David
Dangoor, Stefan Elving, Inger Holmström, Anthon Jahreskog, Brit
Stakston and Paula Zeilon

· re-election of David Dangoor as Board Chairman
· re-election of the registered Accounting firm Deloitte AB
· Board member compensation in an amount of SEK 300,000 to the
Chairman and SEK 150,000 to each of the other Board members not
employed by the company

· auditors' fee shall be paid according to approved account
· regarding principles for remuneration and other terms of
employment for senior executives in accordance with the Board's

· regarding the Nominating Committee in accordance with the
Nominating Committee's proposal

Latest press releases from BioGaia
2016-05-10 BioGaia AB Interim management statement 1 January - 31
March 2016

2016-05-02 Yet another meta-analysis confirms the effectiveness of
BioGaia's probiotic in infantile colic

2016-04-27 BioGaia guarantees rights issue in IBT
For additional information please contact
Axel Sjöblad, Managing Director, BioGaia: +46 8 555 293 00

BioGaia is a healthcare company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri
which has probiotic, health-enhancing effects. The class B share of
the Parent Company BioGaia AB is quoted on the Mid Cap list of NASDAQ
Stockholm main market.



Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.